Total Payments
$760,604
2024 Payments
$228,015
Companies
32
Transactions
382
Medicare Patients
1,373
Medicare Billing
$229,655
Payment Breakdown by Category
Consulting$647,407 (85.1%)
Travel$42,739 (5.6%)
Other$37,688 (5.0%)
Research$22,967 (3.0%)
Food & Beverage$9,744 (1.3%)
Education$58.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $647,407 | 148 | 85.1% |
| Travel and Lodging | $42,739 | 51 | 5.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $33,928 | 12 | 4.5% |
| Unspecified | $22,967 | 24 | 3.0% |
| Food and Beverage | $9,744 | 141 | 1.3% |
| Honoraria | $3,760 | 2 | 0.5% |
| Education | $58.40 | 4 | 0.0% |
Payments by Type
General
$737,637
358 transactions
Research
$22,967
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $388,971 | 54 | $0 (2024) |
| ABBVIE INC. | $76,414 | 82 | $0 (2024) |
| Genentech, Inc. | $33,626 | 25 | $0 (2022) |
| PFIZER INC. | $28,496 | 9 | $0 (2021) |
| Celgene Corporation | $28,449 | 22 | $0 (2020) |
| Adaptive Biotechnologies Corporation | $26,327 | 12 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $25,773 | 42 | $0 (2023) |
| Janssen Biotech, Inc. | $23,606 | 18 | $0 (2022) |
| Janssen Global Services, LLC | $17,775 | 12 | $0 (2022) |
| Gilead Sciences, Inc. | $15,122 | 15 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $228,015 | 21 | AstraZeneca Pharmaceuticals LP ($201,932) |
| 2023 | $154,970 | 18 | AstraZeneca Pharmaceuticals LP ($140,994) |
| 2022 | $38,296 | 45 | E.R. Squibb & Sons, L.L.C. ($8,650) |
| 2021 | $64,326 | 47 | AstraZeneca Pharmaceuticals LP ($15,612) |
| 2020 | $43,939 | 25 | Janssen Global Services, LLC ($9,940) |
| 2019 | $80,286 | 81 | AbbVie, Inc. ($13,807) |
| 2018 | $62,042 | 59 | AbbVie, Inc. ($18,513) |
| 2017 | $88,729 | 86 | AbbVie, Inc. ($24,481) |
All Payment Transactions
382 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $17,233.12 | General |
| 11/14/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $29.72 | General |
| 11/11/2024 | Tempus AI, Inc | — | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| 10/22/2024 | Tempus AI, Inc | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 10/10/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $58,484.64 | General |
| 09/04/2024 | Tempus AI, Inc | — | Consulting Fee | Cash or cash equivalent | $2,125.00 | General |
| 09/04/2024 | Tempus AI, Inc | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 08/05/2024 | Tempus AI, Inc | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 06/30/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $59,581.97 | General |
| 06/12/2024 | Tempus AI, Inc | — | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| 06/12/2024 | Tempus AI, Inc | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 05/24/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $6,800.00 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $301.50 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $182.25 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug), KISQALI, SCEMBLIX | Food and Beverage | In-kind items and services | $96.73 | General |
| Category: Immunology | ||||||
| 03/31/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $65,604.98 | General |
| 02/29/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $97.18 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $100.00 | General |
| 01/26/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,027.50 | General |
| Category: Oncology | ||||||
| 12/31/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $81,339.53 | General |
| 12/09/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $136.86 | General |
| Category: Oncology | ||||||
| 09/30/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $39,474.68 | General |
| 08/24/2023 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PCYC-1134M-CA | Pharmacyclics LLC, An AbbVie Company | $4,338 | 7 |
| CC-5013-CLL-010 | Celgene Corporation | $4,267 | 1 |
| PCYC-1142-CA | Pharmacyclics LLC, An AbbVie Company | $4,102 | 5 |
| REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA CLL RECEIVING FIRST-LINE 1L THERAPY IN THE UNITED STATES US | F. Hoffmann-La Roche AG | $3,468 | 1 |
| Celgene - Connect CLL | Celgene Corporation | $2,533 | 1 |
| informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | Pharmacyclics LLC, An AbbVie Company | $1,524 | 1 |
| A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSEDREFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 ABT-199 PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB | F. Hoffmann-La Roche AG | $801.00 | 2 |
| Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents | AstraZeneca Pharmaceuticals LP | $678.62 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 373 | 607 | $151,862 | $45,918 |
| 2022 | 4 | 326 | 608 | $331,690 | $50,606 |
| 2021 | 6 | 333 | 694 | $398,885 | $63,061 |
| 2020 | 7 | 341 | 847 | $450,555 | $70,070 |
Total Patients
1,373
Total Services
2,756
Medicare Billing
$229,655
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 91 | 183 | $35,272 | $13,701 | 38.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 97 | 205 | $46,130 | $11,653 | 25.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 27 | 45 | $11,597 | $4,914 | 42.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 26 | $17,980 | $3,418 | 19.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 31 | $10,945 | $2,772 | 25.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 26 | 26 | $7,150 | $2,634 | 36.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 37 | 38 | $8,398 | $2,222 | 26.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 17 | $7,990 | $1,709 | 21.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $3,187 | $1,674 | 52.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 22 | 24 | $3,214 | $1,223 | 38.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 235 | 424 | $231,080 | $34,080 | 14.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 123 | $64,575 | $11,419 | 17.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 28 | 28 | $23,660 | $3,176 | 13.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 33 | 33 | $12,375 | $1,932 | 15.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 227 | 532 | $289,940 | $44,752 | 15.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 17 | 71 | $35,855 | $6,773 | 18.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 37 | 37 | $38,665 | $6,043 | 15.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 20 | 20 | $16,500 | $2,483 | 15.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 14 | 15 | $10,800 | $1,879 | 17.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 19 | $7,125 | $1,130 | 15.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 156 | 427 | $222,040 | $29,761 | 13.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 51 | 268 | $132,660 | $25,908 | 19.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 31 | 31 | $30,785 | $4,650 | 15.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 27 | 40 | $27,600 | $3,844 | 13.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 33 | 38 | $13,110 | $2,589 | 19.7% |
About Dr. Anthony Mato, MD
Dr. Anthony Mato, MD is a Medical Oncology healthcare provider based in Ithaca, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053473983.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Mato, MD has received a total of $760,604 in payments from pharmaceutical and medical device companies, with $228,015 received in 2024. These payments were reported across 382 transactions from 32 companies. The most common payment nature is "Consulting Fee" ($647,407).
As a Medicare-enrolled provider, Mato has provided services to 1,373 Medicare beneficiaries, totaling 2,756 services with total Medicare billing of $229,655. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Ithaca, NY
- Active Since 12/15/2006
- Last Updated 08/14/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1053473983
Products in Payments
- IMBRUVICA (Drug) $61,628
- CALQUENCE (Drug) $37,503
- Venclexta (Drug) $34,591
- clonoSEQ (Device) $26,327
- VENCLEXTA (Drug) $16,491
- Rituxan (Biological) $15,922
- Revlimid (Drug) $13,655
- Zydelig (Drug) $12,695
- Imbruvica (Drug) $11,799
- VENCLEXTA (Biological) $11,167
- BRUKINSA (Drug) $8,785
- GAZYVA (Biological) $8,739
- Ibrutinib (Drug) $8,440
- Copiktra (Drug) $7,154
- UKONIQ (Drug) $4,626
- LUMOXITI (Biological) $3,425
- PANZYGA (Biological) $2,500
- RUXIENCE (Biological) $1,260
- Venclexta (Biological) $801.00
- Non-Covered Product (Drug) $736.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.